2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.07. Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-Mutant Lung Cancer

P1.07. Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-Mutant Lung Cancer

Back to course

Pdf Summary

This document summarizes a study conducted at Yale University School of Medicine that examined the impact of co-occurring alterations in tumor suppressor genes (TSGs) on the outcomes of patients with EGFR-mutant lung cancer. The study included 101 patients who underwent tumor genomic profiling and were treated with EGFR-targeted therapy. The researchers focused on mutations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1, and PTEN) to categorize the patients into different subgroups.<br /><br />The results showed that mutations in TSGs other than TP53 were associated with worse prognosis in patients with EGFR-mutant lung cancer. Patients with tumors that had a TP53 mutation plus a mutation in at least one additional TSG had significantly worse progression-free survival and overall survival compared to patients with TP53 mutations but no additional TSG mutations, as well as patients with TP53 wild-type tumors.<br /><br />The findings were validated in a separate cohort from the AACR Project GENIE database. The study highlights the importance of identifying TSG alterations beyond TP53 in risk stratification for EGFR-mutant lung cancer, providing insights into the impact of these co-occurring alterations on patient prognosis. The document includes tables and figures presenting survival curves, hazard ratios, and data on the number of patients at risk at different time points. It also provides contact information for a researcher involved in the study.

Asset Subtitle

Paul Stockhammer, Yale School of Medicine, United States

Meta Tag

Speaker Paul Stockhammer, Yale School of Medicine, United States

Topic Poster Listing

Keywords

Yale University School of Medicine

co-occurring alterations

tumor suppressor genes

EGFR-mutant lung cancer

tumor genomic profiling

EGFR-targeted therapy

TP53 mutation

additional TSG mutations

progression-free survival

overall survival